Accueil   Diary - News   All news GAOMA Therapeutics announces its first capital increase and a strategic partnership with the PPRS Group, for the development of its first-in-class drug-candidate GAO-3-02.

GAOMA Therapeutics announces its first capital increase and a strategic partnership with the PPRS Group, for the development of its first-in-class drug-candidate GAO-3-02.

 

This oversubscribed fund raising reaches a total equity investment over € 1.1m. The life sciences Business Angels organizations Simba Santé 3, Angels Santé and Health Angels Rhône-Alpes participated in the round, alongside with PPRS Ventures and private qualified individuals.

 


Jordan Guyon, GAOMA’s Co-founder and CEO, comments: “GAOMA is proud to have achieved this first financing round, which obviously represents a critical step in the development of the project. Such funding will enable GAOMA to properly structure the company, to enrich its governance and to pursue the preclinical development of its lead program GAO-3-02 in epilepsy”.

 

Read the press release